Education
About Us
Working with TipRanks
Follow Us
Kerry Wentworth Insider Profile
4 Followers
Kerry Wentworth, VP, Clinical, Reg & Qual at Agenus, holds 0.00 shares in Flexion Therapeutics (Ticker: FLXN), holds 57.41K shares in Agenus (Ticker: AGEN), holds ― shares in Nuvation Bio (Ticker: NUVB).
Kerry Wentworth has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Kerry Wentworth holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Kerry Wentworth
Kerry Wentworth's Trading History
Agenus
Feb 28, 2014
VP, Clinical, Reg & Qual
Uninformative Sell
25.00K
$134.91K
Flexion Therapeutics
Nov 19, 2021
―
Uninformative Sell
1.25M
$0.00
Nuvation Bio
―
CHIEF REGULATORY OFFICER
―
―
List of latest transactions for each holding click on a transaction to see Kerry Wentworth's performance on stock
You May Also Like
Kerry Wentworth insider profile FAQ
What is the percentage of profitable transactions made by Kerry Wentworth?
The percentage of profitable transactions made by Kerry Wentworth is ―.
What is the average return per transaction made by Kerry Wentworth?
The average return per transaction made by Kerry Wentworth is ―.
What stocks does Kerry Wentworth hold?
Kerry Wentworth holds: AGEN, FLXN, NUVB stocks.
What was Kerry Wentworth’s latest transaction?
Kerry Wentworth latest transaction was an Uninformative Sell of $1.25M.
What was Kerry Wentworth's most profitable transaction?
Kerry Wentworth’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Kerry Wentworth's role in Agenus?
Kerry Wentworth's role in Agenus is VP, Clinical, Reg & Qual.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.